The integration with Navigating Cancer's mobile care management solution will allow patients participating in TD2-managed clinical trials to record adherence and report how they are feeling in real time through a simple-to-use mobile application. This information will be provided to TD2's participating oncology trial sites to enhance the care of patients enrolled in clinical studies. This access to patient-reported experiences on emerging therapies will provide biotechnology and pharmaceutical companies with new insights that could be used to improve trial designs, develop unique clinical trial endpoints and add value in reimbursement decisions.
"Real-time patient-reported data using Navigating Cancer's mobile solution is an important component of the TD2 clinical trial process," said TD2 CEO Stephen Gately, Ph.D. " This data will be used to support more efficient patient-focused clinical trial designs, and to potentially identify regulatory opportunities for new medicines that improve patient symptoms and functional abilities."
"As a company dedicated to improving health outcomes through patient engagement, we believe that providing patients in clinical trials with a convenient, mobile means of reporting their own experiences on an investigative therapy in real time will be a game-changer for patient-centered drug development." said Gena Cook, CEO of Navigating Cancer. "We are excited to partner with TD2 to ensure that patient's experiences are reflected in health outcomes."
About Navigating Cancer
Navigating Cancer is the leading patient engagement platform and mobile care management solution for cancer centers across the United States. For patients, Navigating Cancer provides a single, comprehensive hub that operates with any electronic health record system, enabling them to stay seamlessly informed and engaged in their own care across multiple clinics, caregivers and geographies. For providers, Navigating Cancer offers a convenient, scalable solution for care management and engagement, a vital tool in the evolution to value-based medicine, and an agile means of satisfying current requirements for Meaningful Use, Commission on Cancer and new payment reform models. For more information, visit:https://www.navigatingcancer.com
Translational Drug Development (TD2) is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2's suite of capabilities encourages the timely selection of patient populations most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit: www.td2inc.com. TD2 is a portfolio company of ORIX Healthcare Capital.
About ORIX Healthcare Capital
ORIX Healthcare Capital provides financial and intellectual capital to companies in the healthcare space. Typical investments range from $20 million to $50 million, with the capacity to grow. ORIX Healthcare Capital is a business unit of ORIX USA, a Dallas-based financial services firm known for providing innovative capital solutions that clients need to propel their business to the next level. With more than 1,400 employees spanning seven primary offices across the U.S. and Brazil, ORIX USA and its family of companies hold $7 billion of assets and manage an additional $30 billion, approximately. Our parent company, ORIX Corporation, is a Tokyo-based, publicly owned international financial services company with operations in 36 countries and regions worldwide. ORIX Corporation is listed on the Tokyo (8591) and New York Stock Exchanges (IX). For more information on ORIX Healthcare Capital, visit www.orix.com.